Last reviewed · How we verify
TUB-040
TUB-040 is a Small molecule drug developed by Tubulis GmbH. It is currently in Phase 1 development.
At a glance
| Generic name | TUB-040 |
|---|---|
| Sponsor | Tubulis GmbH |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TUB-040 CI brief — competitive landscape report
- TUB-040 updates RSS · CI watch RSS
- Tubulis GmbH portfolio CI
Frequently asked questions about TUB-040
What is TUB-040?
TUB-040 is a Small molecule drug developed by Tubulis GmbH.
Who makes TUB-040?
TUB-040 is developed by Tubulis GmbH (see full Tubulis GmbH pipeline at /company/tubulis-gmbh).
What development phase is TUB-040 in?
TUB-040 is in Phase 1.
Related
- Manufacturer: Tubulis GmbH — full pipeline
- Compare: TUB-040 vs similar drugs
- Pricing: TUB-040 cost, discount & access